In summary, more relevant to clinical applications, BRD4i-ATRi treatment causes complete tumor regression in chemotherapy-resistant CCOC PDX tumors more so than monotherapy in an ARID1A level-dependent manner. This evidence concerns the gene ARID1A and neoplasm.